PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Industry-Sponsored Delphi Panel Issues PMX-HA Implementation Framework for Endotoxic Septic Shock

PMX-HA consensuspolymyxin B hemoadsorptionDelphi panel (Vantive-sponsored)endotoxic septic shockEndotoxin Activity Assayextracorporeal blood purificationantimicrobial adsorptionCritical Care 2026 Critical Care / ICU

Background Information

Polymyxin B guidelines target septic shock precision therapy.

Polymyxin B hemoadsorption (PMX-HA) offers a targeted intervention for endotoxic septic shock, with potential to improve outcomes when implemented correctly. 20 consensus statements include criteria for endotoxemia assessment, use of the Endotoxin Activity Assay (EAA), and standardized protocols for PMX-HA. The structured framework helps clinicians identify eligible patients, with specific EAA thresholds supporting treatment decisions. However, regulatory approval is still pending in the U.S. Consensus guidelines provide a framework for PMX-HA in septic shock, pending U.S. approval.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Yessayan L, Legrand M, Neyra JA, Davison D, Busse LW, Bender WS, McMahon BA, Eaton J, Morgan-Gray T, Ramberg C, Tolwani A

Citation: Yessayan L, Legrand M, Neyra JA, et al. Consensus recommendations for patient selection and clinical implementation of polymyxin B hemoadsorption in endotoxic septic shock. Critical care (London, England). 2026;30(1). doi:10.1186/s13054-026-06182-8

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.